Please ensure Javascript is enabled for purposes of website accessibility

Drop-Dead Gorgeous Stocks

By Rich Smith - Updated Apr 5, 2017 at 8:07PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What's better than a 52-week low? How about a five-year plunge?

"The idea of buying a former superstar stock at a discount price certainly has its attractions, but you've got to make sure you catch the haft -- not the blade."

So goes the thesis of my weekly column "Get Ready for the Bounce." Therein, I run the 52-week-lows list compiled by through the "wisdom of crowds" meter that we call Motley Fool CAPS. And out the other end comes a list of stocks that have fallen so far, Foolish investors figure they're just bound to bounce back soon.

But is there a way to cash in on fallen angels who've plummeted even further? Perhaps. If a stock that's fallen for one year straight has headroom, then maybe a stock that's fallen even farther, and longer, has room to soar back even higher -- in which case, an apparently left-for-dead stock could offer us a drop-dead gorgeous entry price. We're going to test that thesis today, starting with five stocks that just hit their five-year lows:


Recent Price

CAPS Rating

(5 max):

WuXi PharmaTech  (NYSE:WX)






Arbitron (NYSE:ARB)



Companies are selected from the "New 5-Year Lows" list published on MSN Money on Thursday. CAPS ratings from Motley Fool CAPS.

Left for dead? Or drop-dead gorgeous?
Each of the stocks listed above has shed between 50% and 80% of its value over the past year alone and currently sits at or near its five-year low. Wall Street has left 'em for dead, and Main Street isn't much more optimistic -- the best stocks on the list get only a half-hearted three-star rating.

Yet, today we see the softer side of the Crash. So many stocks have fallen so far already this year, that finally, at long last, fewer and fewer of them are hitting five-year lows. Why, we didn't even have enough five-year bottom-plumbers this week to fill out our full five-stock table! Begging the question: Could this be the bottom? And if so, is it time to go fishing?

If it is indeed time, then I must say that WuXi PharmaTech looks like the best bet of this last bunch of five-year-low stragglers. For those not familiar with the company, WuXi performs outsourced pharmaceutical research for such giants as Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), and Pfizer (NYSE:PFE). Why is that a good business to be in? I'll let our CAPS pitchers fill you in:

The bull case for WuXi PharmaTech

  • acbinvestor introduced us to WuXi earlier this year: "[WuXi PharmaTech] is the best drug research companies in China. With its huge talent pool and the enormous market potential in China, sky is the limit. By setting up the first life science award in China, [WuXi] solidified its leadership status in China. The move enables [WuXi] to establish close ties to Chinese officials, academic researchers, potential talent pool and other industry insiders."
  • According to CAPS All-Star tskephart: "Pharmaceutical R&D is a very expensive part of the pharmaceutical market. I feel their will be a paradigm shift on how global pharmaceutical companies approach research, one of the results will be more outsourcing and collaborations. WuXi is positioned well to take advantage of this shift."
  • The Fool's own TMFBiologyFool agreed back in May: "Pharma is trying to cut costs and there's no better place to get high quality scientists on the cheap than China."

And speaking of cheap ... WuXi sure looks the part. The company sells for a mere 11 P/E despite analysts agreeing that it will increase those earnings by about 25% per year over the next five years.

Because the company only reports its free cash flow at year-end, we don't know how much of those earnings are "real" right now. But last year, the company generated $25 million in free cash flow, and if WuXi is still growing as fast as the analysts think, this year should be even better. Meanwhile, WuXi has plenty of cash on the balance sheet and trades for only 1.2 times book value.

Now mind you, WuXi's not my favorite play on Chinese medicine. If push came to shove, I'd probably prefer China Medical Technologies (NASDAQ:CMED) over WuXi, and I like Mindray Medical (NYSE:MR) best of all. But that doesn't change the fact that any way you look at it, WuXi qua WuXi looks like a bargain.

Time to chime in
Of course, that's just my opinion. Click on over to Motley Fool CAPS and tell us yours.

Motley Fool CAPS : It's fun, it's free, and it just might make you famous.

Fool contributor Rich Smith does not own shares of any company named above. You can find him on CAPS, publicly pontificating under the handle TMFDitty, where he's currently ranked No. 1935 out of more than 120,000 members. The Fool has a disclosure policy.

Pfizer and Eli Lilly are Motley Fool Income Investor picks. Pfizer is a Motley Fool Inside Value recommendation. Mindray Medical is a Rule Breakers selection. The Fool owns shares of Pfizer and Mindray Medical International. Try any of our Foolish newsletters today, free for 30 days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$89.19 (-0.37%) $0.33
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$304.61 (0.53%) $1.59
Pfizer Inc. Stock Quote
Pfizer Inc.
$49.95 (0.34%) $0.17
Mindray Medical International Limited Stock Quote
Mindray Medical International Limited

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.